F. Hoffmann-la Roche Ag

European Molecular Biology Laboratory

Savira Pharmaceuticals Gmbh

Rd&c Research, Development & Consulting Gmbh

Norbert Handler

Helmut Heinrich Buschmann

Stephen Cusack

Sung-Sau So

Achyutharao Sidduri

Werner Neidhart

Mark Smith

Oliver Szolar

Andrea Wolkerstorfer

Tanja Schulz-Gasch

Robert James Weikert

Franz-Ferdinand Roch

Zhuming Zhang

Bruno Giethlen

Christophe Morice

Thibault Sauvaitre

Céline Simon

Thierry Langer

Dirk Classen-Houben

Céline Michaut-Simon

Thibault SAUVAÎTRE

Subject matter of the present invention are kits comprising containers with at least one solid catalytically active compound, their uses in processes for simulating and predicting the transformation of a compound that is preferably a solid active pharmaceutical ingredient (API), preferably an API in combination with an excipient, in a shortened time span, into the respective degradation product(s).

Kits comprising containers with at least one solid catalytically active compound, and their uses in solid state reaction

The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease

The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Substituted 1,5-naphthyridines as endonuclease inhibitors

The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

The present invention relates to a compound having the general formula (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease

The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

Growing community of inventors

Vienna, Austria

Norbert Handler